Size | Price | Stock | Qty |
---|---|---|---|
500μg |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: =98.88%
Zoliflodacin (formerly ETX-0914; AZD-0914; ETX0914; AZD0914) is a novel and potent spiropyrimidinetrione-based bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin exhibits strong in vitro antibacterial activity against both Gram-positive and Gram-negative bacteria, including S. aureus with the MIC90 of 0.25 μg/mL. With regard to important Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with documented fluoroquinolone resistance, AZD0914 exhibits strong in vitro antibacterial activity. In contrast to other commercially available antibacterial compounds, AZD0914 inhibits DNA biosynthesis and the accumulation of double-strand cleavages. Under permissive conditions, AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA, preventing the double-strand cleaved DNA from religating to form fused circular DNA. This mechanism is different in terms of mechanics even though it is comparable to that of fluoroquinolones. In S. aureus, AZD0914 showed low frequencies of spontaneous resistance; if mutants were obtained, they mapped to gyrB. Furthermore, AZD0914 did not exhibit any cross-resistance against recent clinical isolates of bacteria that were resistant to fluoroquinolones or other drug classes, such as glycopeptides, β-lactams, macrolides, and oxazolidinones. In vitro time-kill studies and minimum bactericidal concentration tests, AZD0914 demonstrated bactericidal activity. Only additivity or indifference was seen in in vitro checkerboard/synergy testing using 17 comparator antibacterials. AZD0914's low frequency of resistance, lack of cross-resistance, strong in vitro antibacterial activity (including activity against isolates resistant to fluoroquinolones), and bactericidal activity all contribute to its continued development.
Targets |
Quinolone
|
|
---|---|---|
ln Vitro |
|
|
Cell Assay |
|
|
References |
Molecular Formula |
C22H22N5O7F
|
---|---|
Molecular Weight |
487.438
|
Exact Mass |
487.15
|
Elemental Analysis |
C, 54.21; H, 4.55; F, 3.90; N, 14.37; O, 22.98
|
CAS # |
1620458-09-4
|
Appearance |
Solid powder
|
SMILES |
C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
|
InChi Key |
ZSWMIFNWDQEXDT-ZESJGQACSA-N
|
InChi Code |
InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
|
Chemical Name |
(4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
|
Synonyms |
Zoliflodacin; ETX0914; AZD-0914; ETX-0914; AZD0914; ETX 0914; AZD 0914
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~140 mg/mL (~287.2 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0515 mL | 10.2577 mL | 20.5153 mL | |
5 mM | 0.4103 mL | 2.0515 mL | 4.1031 mL | |
10 mM | 0.2052 mL | 1.0258 mL | 2.0515 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03959527 | Active Recruiting |
Drug: zoliflodacin Drug: ceftriaxone |
Gonorrhea | Global Antibiotics Research and Development Partnership |
November 6, 2019 | Phase 3 |
NCT03404167 | Completed | Drug: AZD0914 | Gonorrhoea | National Institute of Allergy and Infectious Diseases (NIAID) |
February 2, 2018 | Phase 1 |
NCT03718806 | Completed | Other: high calorie, high fat breakfast Drug: Zoliflodacin |
Gonorrhea | Drugs for Neglected Diseases | October 3, 2018 | Phase 1 |
NCT05635305 | Completed | Drug: Zoliflodacin Patheon | Healthy Volunteers | Global Antibiotics Research and Development Partnership |
November 9, 2022 | Phase 1 |
NCT02257918 | Completed | Drug: AZD0914 Drug: Ceftriaxone |
Gonorrhoea | National Institute of Allergy and Infectious Diseases (NIAID) |
November 25, 2014 | Phase 2 |
In vitrotime-kill performance of AZD0914 (MIC, 0.25 μg/ml) against levofloxacin-resistant MRSA (USA100).Antimicrob Agents Chemother. 2015 Jan; 59(1): 467–474. |
In vitrotime-kill performance of AZD0914 (MIC, 0.25 μg/ml) against S. pneumoniae ATCC 49619.Antimicrob Agents Chemother. 2015 Jan; 59(1): 467–474. td> |
PAE of AZD0914 (MIC, 0.25 μg/ml) againstS. pneumoniaeATCC 49619.Antimicrob Agents Chemother. 2015 Jan; 59(1): 467–474. td> |